Literature DB >> 30580779

Peroneal bypass versus endovascular peroneal intervention for critical limb ischemia.

Abhisekh Mohapatra1, Aureline Boitet2, Othman Malak2, Jon C Henry2, Efthimios D Avgerinos2, Michel S Makaroun2, Eric S Hager2, Rabih A Chaer2.   

Abstract

OBJECTIVE: The peroneal artery is a well-established target for bypass in patients with critical limb ischemia (CLI). The objective of this study was to evaluate the outcomes of peroneal artery revascularization in terms of wound healing and limb salvage in patients with CLI.
METHODS: Patients presenting between 2006 and 2013 with CLI (Rutherford 4-6) and isolated peroneal runoff were included in the study. They were divided into patients who underwent bypass to the peroneal artery and those who underwent endovascular peroneal artery intervention. Demographics, comorbidities, and follow-up data were recorded. Wounds were classified by Wound, Ischemia, foot Infection (WIfI) score. The primary outcome was wound healing; secondary outcomes included mortality, major amputation, and patency.
RESULTS: There were 200 limbs with peroneal bypass and 138 limbs with endovascular peroneal intervention included, with mean follow-up of 24.0 ± 26.3 and 14.5 ± 19.1 months, respectively (P = .0001). The two groups were comparable in comorbidities, with the exception of the endovascular group's having more patients with cardiac and renal disease and diabetes mellitus but fewer patients with smoking history. Based on WIfI criteria, ischemia scores were worse in bypass patients, but wound and foot infection scores were worse in endovascular patients. Perioperatively, bypass patients had higher rates of myocardial infarction (4.5% vs 0%; P = .012) and incisional complications (13.0% vs 4.4%; P = .008). At 12 months, the bypass group compared with the endovascular group had better primary patency (47.9% vs 23.4%; P = .002) and primary assisted patency (63.6% vs 42.2%; P = .003) and a trend toward better secondary patency (74.2% vs 63.5%; P = .11). There were no differences in the rate of wound healing (52.6% vs 37.7% at 1 year; P = .09) or freedom from major amputation (81.5% vs 74.7% at 1 year; P = .37). In a multivariate analysis, neuropathy was associated with improved wound healing, whereas WIfI wound score, cancer, chronic renal insufficiency, and smoking were associated with decreased wound healing. Treatment modality was not a significant predictor (P = .15).
CONCLUSIONS: Endovascular peroneal artery intervention results in poorer primary and primary assisted patency rates than surgical bypass to the peroneal artery but provides similar wound healing and limb salvage rates with a lower rate of complications. In appropriately selected patients, endovascular intervention to treat the peroneal artery is a low-risk intervention that may be sufficient to heal ischemic foot wounds.
Copyright © 2018 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Critical limb ischemia; Lower extremity bypass; Peripheral arterial disease; Peroneal artery; Wound healing

Mesh:

Year:  2018        PMID: 30580779      PMCID: PMC6310052          DOI: 10.1016/j.jvs.2018.04.049

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  17 in total

Review 1.  Patterns of disease distribution of lower extremity peripheral arterial disease.

Authors:  Qian Chen; Yang Shi; Yutang Wang; Xiaoying Li
Journal:  Angiology       Date:  2014-03-19       Impact factor: 3.619

2.  Infrapopliteal percutaneous transluminal angioplasty versus bypass surgery as first-line strategies in critical leg ischemia: a propensity score analysis.

Authors:  Maria I Söderström; Eva M Arvela; Maria Korhonen; Karoliina H Halmesmäki; Anders N Albäck; Fausto Biancari; Mauri J Lepäntalo; Maarit A Venermo
Journal:  Ann Surg       Date:  2010-11       Impact factor: 12.969

Review 3.  Inter-society consensus for the management of peripheral arterial disease.

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes; R B Rutherford
Journal:  Int Angiol       Date:  2007-06       Impact factor: 2.789

4.  Recommended standards for reports dealing with lower extremity ischemia: revised version.

Authors:  R B Rutherford; J D Baker; C Ernst; K W Johnston; J M Porter; S Ahn; D N Jones
Journal:  J Vasc Surg       Date:  1997-09       Impact factor: 4.268

Review 5.  The natural history of untreated severe or critical limb ischemia.

Authors:  Abd Moain Abu Dabrh; Mark W Steffen; Chaitanya Undavalli; Noor Asi; Zhen Wang; Mohamed B Elamin; Michael S Conte; Mohammad Hassan Murad
Journal:  J Vasc Surg       Date:  2015-09-26       Impact factor: 4.268

Review 6.  The Current State of Critical Limb Ischemia: A Systematic Review.

Authors:  Alik Farber; Robert T Eberhardt
Journal:  JAMA Surg       Date:  2016-11-01       Impact factor: 14.766

7.  Angiographic runoff score as a predictor of outcome following femorocrural bypass surgery.

Authors:  F Biancari; A Albäck; L Ihlberg; I Kantonen; M Luther; M Lepäntalo
Journal:  Eur J Vasc Endovasc Surg       Date:  1999-06       Impact factor: 7.069

8.  The peripheral arterial disease study (PERART/ARTPER): prevalence and risk factors in the general population.

Authors:  María Teresa Alzamora; Rosa Forés; José Miguel Baena-Díez; Guillem Pera; Pere Toran; Marta Sorribes; Marisa Vicheto; María Dolores Reina; Amparo Sancho; Carlos Albaladejo; Judith Llussà
Journal:  BMC Public Health       Date:  2010-01-27       Impact factor: 3.295

9.  Peroneal artery-only runoff following endovascular revascularizations is effective for limb salvage in patients with tissue loss.

Authors:  Hasan H Dosluoglu; Gregory S Cherr; Purandath Lall; Linda M Harris; Maciej L Dryjski
Journal:  J Vasc Surg       Date:  2008-05-23       Impact factor: 4.268

10.  Predictive ability of the Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification system following infrapopliteal endovascular interventions for critical limb ischemia.

Authors:  Jeremy D Darling; John C McCallum; Peter A Soden; Yifan Meng; Mark C Wyers; Allen D Hamdan; Hence J Verhagen; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2016-07-02       Impact factor: 4.268

View more
  1 in total

1.  Jujuboside B Inhibits Neointimal Hyperplasia and Prevents Vascular Smooth Muscle Cell Dedifferentiation, Proliferation, and Migration via Activation of AMPK/PPAR-γ Signaling.

Authors:  Zaixiong Ji; Jiaqi Li; Jianbo Wang
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.